" class="no-js "lang="en-US"> Stéphane Bancel - Medtech Alert
Monday, June 17, 2024
Stephane Bancel

Stéphane Bancel

About Stéphane Bancel

Related Story

James Mock Joins Moderna as Chief Financial Officer

August 19 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-containing Bivalent Booster in the UK

August 17 2022

Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna and the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-containing Bivalent Candidates; EC Purchases Additional 15 Million Doses

August 11 2022

Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an […]

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

July 26 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that […]

Moderna's Omicron-containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared to Currently Authorized Booster

July 14 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces First Participant Dosed in a Phase 1 Trial of Its Nipah Virus mRNA Vaccine, mRNA-1215

July 14 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces Bivalent Booster mRNA -1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants Ba.4 and Ba.5

June 24 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

June 22 2022

Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces Omicron-containing Bivalent Booster Candidate Mrna-1273.214 Demonstrates Superior Antibody Response Against Omicron

June 10 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day

May 19 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, today announced new […]

Arpa Garay Joins Moderna as Chief Commercial Officer

April 28 2022

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023

December 3 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

November 29 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces EU and EEA Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to Help End COVID-19 Pandemic in Low Income Countries

November 16 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022

October 14 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year

October 8 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

October 6 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today […]

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

August 11 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Dr. Paul Burton to Join Moderna as Chief Medical Officer

June 15 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union

June 8 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility

June 2 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and UNICEF today announced […]

Moderna Announces TeenCOVE Study of COVID-19 Vaccine (mRNA-1273) in Adolescents Meets Primary Endpoint

May 27 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine

May 13 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses

May 6 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]

Moderna Expands Manufacturing Technology Center

May 5 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

Moderna New Supply Agreement with Israel for 2022

April 21 2021

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a […]

Moderna announces FDA Authorization of Moderna COVID-19 vaccine in U.S.

December 18 2020

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that […]